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The increase in allergy to peanut in westernised 
countries[1] has sparked widespread interest in peanut 
allergy. Recent progress has been made in identifying 
risk factors for peanut allergy, such as epithelial 
barrier defects leading to epicutaneous sensitisation 
by peanut protein.[2] Further research into possible strategies to 
prevent peanut allergy in high-risk patients has favoured early 
introduction of peanut protein, which may promote tolerance in 
selected patients.[3] Screening for peanut allergy is an important 
part of the management of the patient at risk of peanut allergy. 
However, sensitisation does not equate to allergy in peanut-sensitised 
patients, and further specialised tests such as food challenges may be 
required to differentiate between asymptomatically sensitised and 
truly allergic patients. Ninety-five percent positive predictive values 
(PPVs) have been established to predict food allergies more reliably 
and reduce the number of labour-intensive and potentially hazardous 
food challenges. However, these PPVs may be population and age 
specific.[4]
The use of molecular allergology using component-resolved 
diagnostics has become commonplace in peanut allergy diagnosis 
in the past decade. Peanut components are prefixed ‘Ara’ after 
the name for peanut, Arachis hypogaea. Component testing for 
peanut proteins helps differentiate between nonspecific cross-
reactive components such as Ara h 5, 8 and 9 and specific peanut 
components such as Ara  h  1, 2, 3 and 6, which are heat-resistant 
storage proteins. Ara h 2 (2S albumin storage protein) has been 
shown to be the most important component in prediction of food 
allergy in several countries, including the UK,[5] France,[6] Japan[7] 
and the USA,[8] with a positive result (>0.35  kU/L) to Ara h 2 
having a high predictive value for peanut allergy. In Medi terranean 
countries, the lipid transfer factor Ara h 9 is an important peanut 
allergen.[9] Ara h 8, in the PR10 protein group of labile food 
allergens, is more prominent in those exposed to certain pollens 
such as birch and alder.[10] The pattern and relevance of peanut 
components may therefore vary between geographical areas and 
possibly between ethnic groups.
Currently there are no reliable data on peanut allergy prevalence 
in South Africa (SA), but prevalence studies are underway. A recent 
study on food allergy prevalence in patients with atopic dermatitis 
(AD) suggests a high rate of peanut allergy of 25% in this high-risk 
population.[11] However, the rate of asymptomatic sensitisation was 
also high: a further 19% of patients were peanut sensitised but not 
allergic. The objective of this study was to determine parameters 
that may help in differentiating between peanut allergy and 
asymptomatic sensitisation in our cohort of children with AD. It is 
the first study in SA to utilise oral food challenge tests in equivocal 
cases, and also the first to analyse peanut component patterns. 
Patterns of peanut component sensitisation (Ara h 1, 2, 3, 8 and 
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Background. Diagnosing peanut allergy based on sensitisation alone leads to an unacceptable rate of overdiagnosis.
Objective. To define parameters that may help differentiate peanut allergy from asymptomatic sensitisation in a cohort of South African 
(SA) children with atopic dermatitis (AD). It is the first study in SA to utilise oral food challenge tests and analyse peanut component 
patterns.
Methods. This was a prospective, observational study at a paediatric university hospital in Cape Town, SA. Children with AD, aged 6 
months - 10 years, were recruited randomly. They were assessed for sensitisation and allergy to peanut by questionnaire, skin-prick tests 
(SPTs), immuno solid-phase allergen chip (ISAC) tests, ImmunoCAP component tests to Ara h 1, 2, 3, 8 and 9, and incremental food 
challenges.
Results. One hundred participants (59 Xhosa (black Africans) and 41 of mixed race, median age 42 months) were enrolled. Overall, 44% 
of patients were peanut sensitised and 25% had a true peanut allergy. SPTs and ImmunoCAP Ara h 2 produced the highest areas under the 
receiver operating characteristic curve for predicting peanut allergy in peanut-sensitised patients. The ISAC test was less sensitive, more 
specific and produced significantly lower median values than ImmunoCAP tests. Ara h 2 was the most useful component in differentiating 
allergy from tolerance in both ethnic groups, being positive in 92% of allergic and 40% of sensitised but tolerant children (p<0.001). 
There was little additional contribution from Ara h 1 and 3. Ara h 8 and 9 were associated with tolerance. Commonly used 95% positive 
predictive values (PPVs) for SPTs, peanut-specific IgE and Ara h 2 levels fared suboptimally in our population. Maximum PPVs for this 
study population were found at SPT 11 mm, peanut IgE 15 kU/L and ImmunoCAP Ara h 2 of 8 kU/L, but these adjusted levels still had 
suboptimal PPVs in Xhosa subjects. Severe peanut allergy was associated with increased median peanut IgE and Ara h 2.
Conclusions. The component Ara h 2 was useful for differentiating allergy from tolerance in both ethnic groups in this SA cohort. Ninety-
five percent PPVs for peanut allergy tests may need to be revised, especially in Xhosa patients. An SPT result ≥11 mm as well as Ara h 2 
≥8 kU/L had the best predictive value for peanut allergy.
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9) and the value of internationally derived 95% PPVs for peanut 
allergy were explored.
Methods
The methods have been described in detail in a previous article.[11] 
In brief, 100 children (aged 6 months - 10 years) with moderate 
to severe AD were randomly selected from a dermatology clinic at 
Red Cross War Memorial Children’s Hospital (RCWMCH), Cape 
Town, SA. They completed an allergy questionnaire and underwent 
eczema scoring by SCORAD (SCORing Atopic Dermatitis) 
assessment, and a panel of skin-prick tests (SPTs) including peanut 
extract (Alk Abello, Spain). They all underwent an ImmunoCAP 
immuno solid-phase allergen chip (ISAC) 103 microarray test that 
tested for peanut components Ara h 1, 2, 3 and 8. The patients 
who were sensitised to peanut by the SPT or ISAC test (n=44) 
further underwent ImmunoCAP testing to whole-peanut extract 
and components, Ara h 1, 2, 3, 8 and 9 (Phadia, Sweden). In all 
patients in whom there was uncertainty regarding peanut allergy, 
an incremental open food challenge was performed as a day case 
at RCWMCH. The challenge food was given in the form of peanut 
butter, starting with a lip challenge then moving from 0.3 g to 17 g 
of peanut butter over 2 hours with dose increments every 15 - 20 
minutes.
Study definitions
IgE-mediated peanut sensitisation was defined as a positive SPT 
(≥3 mm above the negative control) and/ or positive food-specific IgE 
by ISAC (≥0.3 ISAC units).
IgE-mediated peanut allergy was defined as either a positive 
food challenge or a convincing clinical history of significant type I 
allergic reactions after isolated ingestion of peanut-containing food 
in the preceding 6 months, with significantly positive SPT/specific 
IgE above the 95% PPV for peanut of 8 mm for SPT and 14 kU/L for 
ImmunoCAP.[12,13]
Ethical considerations
The study was approved by the University of Cape Town’s Faculty of 
Science Human Ethics committee (reference 426/2009). Informed 
consent was obtained from a parent/legal guardian for study 
participation, food challenges and blood testing.
Data entry and statistics
Data were entered onto a computerised database using STATA 
version 11.1 (Stata Corp, USA). Statistical tests were performed 
according to parametric or non-parametric distribution of data 
for comparisons between continuous parameters and categorical 
variables. The χ2 test or the two-sample test of proportion was 
used to test for statistical differences between proportions. A 
p-value of <0.05 was considered statistically significant. Receiver 
operating characteristic (ROC) curves were used to assess the 
capacity of a variable or component to diagnose food allergy. 
Specificity, sensitivity and PPVs were calculated at various cut-off 
levels.
Results
Peanut sensitisation and allergy patterns
Overall, 44% of the patients (n=44) were sensitised to peanut (40% 
(24/59) of Xhosa (black African) patients and 50% (20/40) of mixed-
race patients (p=0.1)). Overall, 24% (n=24) of the patients were 
peanut allergic (15% (9/59) of Xhosa patients and 38% (15/40) of 
mixed-race patients). The inter-ethnic difference was significant 
(p=0.01) (Fig. 1).
Overall, 57% of peanut-sensitised patients were peanut-allergic; this 
ratio was 75% in children of mixed race and 38% in Xhosas, and was 
significantly different at p<0.001.
Value of history of past reaction to peanut allergy  
in the diagnosis of peanut allergy
Overall, 23% of the patients (n=23) reported a reaction to peanut, 
of whom 16 were found to be allergic; 70% (16/23) with a perceived 
peanut allergy therefore had a true peanut allergy. Eight patients 
who were subsequently found to be allergic had never eaten peanut 
before.
Symptoms of a severe reaction such as wheeze, tight throat and 
circulatory compromise were 100% accurate in predicting peanut 
allergy, as was an itchy mouth. However, symptoms such as perceived 
angio-oedema and eczema exacerbation had a poor predictive value 
(Table 1).
Sensitivity and specificity of positive SPTs, ISAC tests 
and ImmunoCAP tests in differentiating peanut allergy 
from tolerance in peanut-sensitised patients (n=44)
Patients who were found to be sensitised to peanut by the screening 
SPTs/ISAC tests underwent ImmunoCAP tests to whole peanut and 
components Ara h 1, 2, 3, 8 and 9 (n=44). A positive test result was 
Table 1. Reported symptoms caused by peanut and their 
predictive values
Symptom
Patients with 
history of reaction 
to peanut
n/N (%)
Proportion of patients 
with this symptom 
who were found to 
have peanut allergy
n/N (%)
Itchy rash 15/23 (65) 10/15 (67)
Angio-oedema 9/23 (39) 5/9 (56)
Exacerbation of eczema 9/23 (39) 5/9 (56)
‘Doesn’t like’ the food 7/23 (30) 5/7 (71)
Flushing 5/23 (22) 4/5 (80)
Wheeze 5/23 (22) 5/5 (100)
Vomiting 4/23 (17) 3/4 (75)
Itchy mouth 3/23 (13) 3/3 (100)
Tight throat 3/23 (13) 3/3 (100)
Circulatory compromise 
(blue lips, shock)
1/23 (4) 1/1 (100)
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Fig. 1. Proportions of patients with peanut sensitisation and allergy, by 
ethnic group.
RESEARCH
216       February 2016, Vol. 106, No. 2
considered to be ≥3 mm for SPT, ≥0.35 
kU/L for ImmunoCAP tests and ≥0.3 ISAC 
units/L for ISAC tests.
In the 44 peanut-sensitised patients, 
the highest sensitivity for diagnosis of 
peanut allergy was achieved by both the 
SPT and the ImmunoCAP test to whole 
peanut, at 100% in both ethnic groups. 
However, the specificity of these tests and 
the PPV was poor: for SPT ≥3 mm the 
specificity was 73% and the PPV 55%, 
and for ImmunoCAP Peanut ≥0.35 kU/L 
the specificity was 40% and the PPV 67%. 
Component testing for Ara h 2 by both ISAC 
test and the ImmunoCAP test produced 
lower sensitivities than the SPT but higher 
specificities and PPVs: for ISAC Ara h 
2 ≥0.3 ISAC units, sensitivity for peanut 
allergy diagnosis was 83%, specificity 75% 
and PPV 80%, and for ImmunoCAP to Ara 
h 2 sensitivity was 92%, specificity 60% and 
PPV 73%. Sensitivities, specificities and 
PPVs for peanut-sensitised patients are set 
out in Table 2.
The trend for all the above screening tests 
was towards a lower specificity and PPV in 
the Xhosa patients, as depicted in Table 2.
ROC curves for diagnosis of 
peanut allergy  in peanut-sensitised 
patients
ROC curves were performed to assess the 
capacity of variables to diagnose peanut 
allergy in peanut-sensitised patients. The 
highest area under the ROC curve (AUC) 
was attained for SPT to peanut (0.94), 
followed by ImmunoCAP Ara h 2 and ISAC 
Ara h 2 (both 0.86), then ImmunoCAP 
to whole peanut (0.80). The ROC AUC 
was significantly lower for Ara h 1, both 
by ISAC (AUC 0.62) and ImmunoCAP 
(AUC 0.68), and for Ara h 3 for ISAC 
(AUC 0.62) and ImmunoCAP (AUC 0.64). 
Performance in the prediction of peanut 
allergy was poor for ImmunoCAP Ara h 8 
(AUC 0.56) and Ara h 9 (AUC 0.51). The 
ROC AUC results and ethnic comparisons 
for peanut-sensitised patients are depicted 
in Table 3 and Fig. 2.
Table 2. Sensitivities and specificities of SPTs, ISAC tests and ImmunoCAP tests for 
predicting peanut allergy in peanut-sensitised patients
Overall 
(N=44), %
Xhosa 
(n=24), %
Mixed race 
(n=20), %
Difference between ethnic 
groups (p-value by χ2 test)
SPT peanut ≥3 mm
Sensitivity 100 100 100 1.0
Specificity 73 70 80 0.45
PPV 55 38 75 0.01
NPV 100 100 100 1.0
ImmunoCAP 
Peanut  
≥0.35 kU/L
Sensitivity 100 100 100 1.0
Specificity 40 33 60 0.07
PPV 67 47 88 0.004
NPV 100 100 100 1.0
ISAC Ara h 2  
≥0.3 ISAC units
Sensitivity 83 78 87 0.44
Specificity 75 67 100 0.005
PPV 80 58 100 0.001
NPV 79 83 71 0.34
ImmunoCAP  
Ara h 2 ≥0.35 kU/L
Sensitivity 92 89 93 0.65
Specificity 60 53 80 0.06
PPV 73 53 93 0.004
NPV 86 89 80 0.41
NPV = negative predictive value.
Table 3. ROC graphs for SPT, peanut ImmunoCAP and peanut components as predictors of peanut allergy in peanut-sensitised 
patients
ROC overall (N=44)
AUC (95% CI)
ROC Xhosa (n=24)
AUC (95% CI)
ROC mixed race (n=20)
AUC (95% CI)
Difference in AUC between 
ethnic groups (p-value)
SPT peanut 0.94 (0.87 - 1) 0.91 (0.78 - 1) 1 (1 - 1) 0.15
ImmunoCAP Peanut 0.80 (0.66 - 0.94) 0.76 (0.55 - 0.96) 0.87 (0.69 - 1) 0.40
ISAC Ara h 1 0.62 (0.47 - 0.77) 0.50 (0.29 - 0.72) 0.8 (0.67 - 0.93) 0.02*
ISAC Ara h 2 0.86 (0.76 - 0.97) 0.79 (0.59 - 0.98) 0.93 (0.84 - 1) 0.18
ISAC Ara h 3 0.62 (0.49 - 0.75) 0.48 (0.34 - 0.62) 0.77 (0.64 - 0.89) 0.003*
ImmunoCAP Ara h 1 0.68 (0.48 - 0.89) 0.64 (0.37 - 0.91) 0.77 (0.55 - 0.99) 0.48
ImmunoCAP Ara h 2 0.86 (0.74 - 0.98) 0.85 (0.69 - 1) 0.91 (0.76 - 1) 0.60
ImmunoCAP Ara h 3 0.64 (0.44 - 0.84) 0.53 (0.27 - 0.8) 0.8 (0.49 - 1) 0.26
ImmunoCAP Ara h 8 0.56 (0.37 - 0.76) 0.43 (0.37 - 0.89) 0.63 (0.37 - 0.89) 0.31
ImmunoCAP Ara h 9 0.51 (0.31 - 0.71) 0.35 (0.08 - 0.61) 0.7 (0.19 - 1) 0.22
CI = confidence interval.
*Statistically significant by χ2 test.
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Peanut component patterns
Peanut component testing in the overall study population (n=99)
Of the 100 patients, 99 completed their peanut allergy investigations. 
In this group, the proportion of patients who tested positive was 
significantly higher for all three ISAC components in peanut-allergic 
v. tolerant patients (p<0.001 for all components Ara h 1, 2 and 3), as 
depi cted in Fig. 3.
Peanut component testing in peanut-sensitised patients (n=44)
Overall, in the 44 peanut-sensitised patients, the most common 
peanut components by ImmunoCAP were Ara h 2 (69%), Ara 
h 1 (62%), Ara h 3 (58%), Ara h 9 (49%) and Ara h 8 (33%). 
ImmunoCAP Ara h 2 was 92% positive in peanut-allergic patients v. 
40% positive in peanut-tolerant patients (p<0.001.) The significant 
trend in Ara h 2 positivity in allergic patients was followed in 
both ethnic groups: in Xhosa patients, 89% of allergic v. 47% of 
tolerant patients were Ara h 2-positive (p=0.04), and in mixed-
race patients 93% of peanut-allergic and 20% of tolerant patients 
were Ara h 2-positive (p=0.001). The components ImmunoCAP 
Ara h 1 and ImmunoCAP Ara h 3 were not significantly different 
between allergic and tolerant patients in this peanut-sensitised 
group, both overall and in each ethnic group (Fig. 4). In all cases 
of peanut allergy with Ara h 1 and/or 3 positivity, Ara h 2 was also 
positive. Ara h 8 and 9 were higher in tolerant than allergic patients 
in both ethnic groups, and this reached statistical significance in 
the Xhosa group for Ara h 9, and was significantly more frequent 
in non-allergic patients (p=0.04). In all but one case of Ara h 8 
positivity, Ara h 9 was also positive. In the Xhosa population, Ara 
h 9 therefore seems to be the most useful test in assessing tolerance 
by cross-reactivity.
When analysing the best predictive combination of components for 
predicting peanut allergy, Ara h 2 positivity was 73% predictive of 
true peanut allergy in the overall population. If Ara h 1 and 2 were 
positive (n=16) this increased to 80%, and if Ara h 1 and 2 were 
positive and Ara h 9 was negative (n=9) the predictive value became 
100% for peanut allergy in both ethnic groups.
By ISAC components, the proportion of patients with sensitisation 
to Ara h 2 and Ara h 3, as well as Ara h 1 in mixed-race patients 
only, was significantly higher in allergic patients. Peanut component 
distribution in allergic and tolerant patients is set out in Table 4.
Despite the overall superiority of Ara h 2 in differentiating allergy 
from tolerance in both ethnic groups, the Xhosa patients had a 
significantly higher false-positive rate. The likelihood of being peanut 
allergic given a positive ImmunoCAP Ara h 2 was significantly lower 
wSimilarly, for a positive ISAC Ara h 2 test, the chance of peanut 
allergy was 58% for Xhosa patients v. 100% for mixed-race patients 
(p=0.009).
Value of internationally derived 95% PPVs
The sensitivities, specificities and PPVs in diagnosing peanut allergy 
were analysed at the internationally derived levels of SPT and specific 
IgE widely used as 95% predictive for peanut allergy: these levels 
were 8 mm for SPT to peanut extract,[12] 14 kU/L for ImmunoCAP 
to peanut,[13] and 0.35 kU/L for ImmunoCap Ara h 2.[5] In the study 
population overall, these cut-off values produced PPVs of 85%, 77% 
and 73%, respectively, for SPT 8 mm, ImmunoCAP Peanut 14 kU/L 
and Ara h 2 0.35 kU/L (Table 5). These cut-off values proved useful in 
the mixed-race population (PPV 88%, 93% and 100%, respectively), 
but were of significantly less predictive value in the Xhosa population 
(80%, 57% and 53%, respectively).
In analysing the cut-off points producing the highest PPV for 
allergies, at an SPT of 11 mm, the PPV was 95% overall (100% for 
mixed-race and 88% for Xhosa patients).
For peanut-specific IgE, a maximum PPV of 80% was attained at a 
level of 15 kU/L (100% for mixed-race and 57% for Xhosa patients). 
For Xhosas, a maximum PPV of only 66% was attained at a level of 
65 kU/L.
For ImmunoCAP Ara h 2, a PPV of 93% was attained at a level of 
8 kU/L for the study population overall, at which level the PPV was 
100% in the mixed-race group and 80% in Xhosas.
For ISAC Ara h 2, a 93% PPV was attained at a level of 1.8 ISAC 
units/L, at which level the mixed-race subgroup had a PPV of 100% 
and the Xhosas a PPV of 83%.
Severe peanut allergy
Five patients (4 of mixed race, 1 Xhosa) had symptoms of severe 
peanut allergy. All 5 were ImmunoCAP Ara h 2- and ISAC Ara h 
2-positive, as well as ISAC Ara h 1-positive; 80% (4/5) were also 
ImmunoCAP Ara h 1- and Ara h 3-positive, and 80% (4/5) were 
ISAC Ara h 3-positive. The presence of ISAC Ara h 1 and ISAC 
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Ara h 3 in addition to a positive ISAC Ara 
h 2 significantly increased the likelihood 
of the allergy being severe, as depicted in 
Table 6.
The median value for ImmunoCAP to 
whole peanut was significantly higher in 
children with severe peanut allergy than in 
those with an allergy but no anaphylactic 
symptoms (88 kU/L v. 12.1 kU/L; p=0.04). 
Similarly, the median value for ImmunoCAP 
Ara h 2 (64.5 kU/L v. 8.98 kU/L; p=0.01) and 
the median ISAC to Ara h 2 (11.0 ISAC units 
v. 2.2 ISAC units; p=0.009) were significantly 
higher in the patients with severe peanut 
allergy.
Comparing ISAC with 
ImmunoCAP tests for peanut 
allergy
In the peanut-sensitised subgroup (n=44), 
in which both ISAC and ImmunoCAP 
tests were performed, these two tests could 
be compared. The ISAC test proved less 
sensitive but more specific for peanut 
allergy than the ImmunoCAP tests. Of 
peanut-allergic patients, 88% tested posi-
tive to at least one ISAC component, and 
83% to ISAC Ara h 2, while 96% tested 
positive to any ImmunoCAP component, 
and 92% to ImmunoCAP Ara h 2 (p=0.35). 
Testing by ISAC components alone would 
have missed 3 cases of peanut allergy 
(12.5%).
Median values for ImmunoCAP com-
ponent levels were significantly higher 
than ISAC values for both allergic and 
tolerant patients. The median Ara h 2 by 
ImmunoCAP in peanut-allergic patients was 
15.25 kU/L, v. 3.6 ISAC units (p<0.001). In 
tolerant patients, the median value for Ara h 
2 by ImmunoCAP was 0.21 kU/L, v. 0 ISAC 
units (p<0.001).
Discussion
This is the first study in SA to explore 
challenge-proven peanut allergy, as well 
as component patterns, and therefore 
provides an opportunity to explore clinical 
and laboratory parameters that most accu-
rately predict peanut allergy. The study 
was performed in children with moderate 
to severe AD, a population known to 
be at significantly higher risk of peanut 
allergy than the general population. Peanut 
sensitisation (44%) and allergy rates (24%) 
were high in our study population, yet the 
rate of asymptomatic sensitisation in our 
study was also significant (43% of sensitised 
patients were found to tolerate peanut). 
Diagnosing peanut allergy based on 
sensitisation alone leads to an unacceptable 
rate of overdiagnosis, unnecessary food 
elimination and anxiety. Moreover, avoiding 
foods unnecessarily in a child’s diet may 
actually abrogate tolerance induction and 
conversely lead to higher eventual allergy 
rates. This has been demonstrated recently 
in the LEAP (Learning Early About Peanut 
Allergy) study, in which children at risk 
of peanut allergy, who were not yet signi-
ficantly sensitised, had lower peanut 
allergy rates at 5 years of age if peanut had 
been introduced into their diet early and 
regularly.[3]
It is therefore important to identify clinical 
and laboratory parameters that may help 
differentiate true allergy from asymptomatic 
sensitisation, and allow patients to be 
selected more prudently for food challenges/
food introduction.
Our study showed that a history of per-
ceived reaction to peanut carried only a 
70% likelihood of a true allergy. Positive 
SPTs and ImmunoCAP Peanut were highly 
Table 4. Peanut component sensitisation in peanut-sensitised patients (N=44)
Patients with positive 
component test
(>0.3 ISAC units for ISAC or 
>0.35 kU/L for ImmunoCAP), %
Difference between 
allergic and 
tolerant patients 
(p-value)
Overall 
allergic (n=24)
Overall 
tolerant (n=20)
ISAC Ara h 1 50 25 0.09
ImmunoCAP Ara h 1 71 50 0.16
ISAC Ara h 2 83 25 <0.001*
ImmunoCAP Ara h 2 92 40 <0.001*
ISAC Ara h 3 38 10 0.04*
ImmunoCAP Ara h 3 54 60 0.7
ImmunoCAP Ara h 8 29 40 0.45
ImmunoCAP Ara h 1- 
+2-positive 
67 20 0.002*
ImmunoCAP Ara h 1- 
+2-positive, Ara h 9-negative
38 0 0.002*
ImmunoCAP Ara h 1- 
+2-negative,  
Ara h 9-positive 
0 45 <0.001* (in favour 
of tolerance)
*Statistically significant by χ2 test.
Table 5. Value of commonly used 95% PPVs in the study population
Overall 
PPV, %
Xhosa 
PPV, %
Mixed race 
PPV, %
Commonly used 95% PPVs
SPT to peanut ≥8 mm 85 80 88
 Immunocap Peanut  
≥14 kU/L
77 57 90
 ImmunoCAP Ara h 2  
≥0.35 kU/L
73 53 93
ISAC Ara h 2 ≥0.3 ISAC units/L 80 58 100
Levels producing maximum PPV for the study population
SPT to peanut ≥11 mm 95 88 100
 ImmunoCAP Peanut  
≥ 15 kU/L
80 57 100
 ImmunoCAP Ara h 2  
≥8.0 kU/L
93 80 100
ISAC Ara h 2 ≥1.8 ISAC units/L 93 83 100
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sensitive but not specific for peanut allergy. 
ROC curves in patients sensitised to peanut 
showed SPT size and Ara h 2 to be most 
valuable parameters in differentiating 
allergy from tolerance. However, the cut-off 
levels above which allergy is likely for these 
parameters were higher in our study than 
previously described.[12,13]
In this study, the pattern of component 
reactivity between the two ethnic groups 
was similar, with Ara h 2 being the superior 
component for differentiating true allergy 
from tolerance. Our study concurs with 
previous studies that Ara h 2 seems to be 
the most important peanut allergen.[5-8] Ara 
h 2 by ImmunoCAP as well as the ISAC test 
were significantly more frequently positive 
in peanut-allergic than in asymptomatically 
sensitised patients. ImmunoCAP Ara h 
2 was positive in 92% of peanut-allergic 
patients, similar to recent studies in China[14] 
(87% positivity) and Japan[7] (88% Ara h 
2-positive). However, the component reac-
tivity among asymptomatically sensitised 
patients was significantly higher in the 
Xhosa population than in the mixed-race 
patients. In Xhosa patients shown to be 
sensitised to Ara h 2 by the ImmunoCAP 
test, the chance of having a peanut allergy 
was significantly lower (53%) than in the 
mixed-race group (93%). Food challenges 
may therefore be of particular importance in 
Xhosa patients with sensitisation to peanut. 
Ethnic differences in peanut sensitisation/
allergy patterns have been described in more 
detail in a previous article.[15]
Little additional benefit was shown from 
ImmunoCAP Ara h 1 and Ara h 3, which 
were not significantly higher in allergic 
patients than in tolerant patients in either 
ethnic group. ImmunoCAP Ara h 8 or 9 
reactivity in the absence of Ara h 2 reactivity 
was highly suggestive of tolerance despite 
a positive SPT or ImmunoCAP to peanut. 
A cost-effective approach to component 
testing in this population would therefore be 
to test Ara h 2 and Ara h 9.
Ninety-five percent PPVs have been deve-
loped as a surrogate to oral food challenges, 
and also to minimise the overdiagnosis of 
food allergy based on laboratory results 
alone. Although there is some variation of 
PPVs for peanut allergy in the international 
literature, a specific IgE level of ≥14 kU/L 
is commonly used,[13] as is an SPT value 
of >8  mm.[12] In a recent British study, an 
excellent performance of Ara h 2 Immuno-
CAP was attained, with 97.5% of patients 
correctly classified as peanut allergic v. 
tolerant at a cut-off of 0.35 kU/L.[5]
However, 95% PPVs may be age and 
population specific. The HealthNuts study, 
performed in infants in Australia, recently 
showed that an SPT of 8 mm had a PPV of 
95% in this population, similar to previous 
studies; however, the serum IgE with a 95% 
PPV for peanut allergy was higher than 
previously quoted, at 34 kU/L.[4] A recent 
Japanese study has suggested an Ara h 2 cut-
off of 4 kU/L to have a 91% PPV for peanut 
allergy,[16] and in a German study a 90% 
probability for positive peanut challenge for 
Ara h 2 was estimated at 14.4 kU/L.[17]
In our population, commonly used PPVs 
for SPT, ImmunoCAP Peanut and Ara h 2 
performed suboptimally at 85%, 77% and 
73%, respectively. Furthermore, there were 
significant ethnic differences, with the Xhosa 
patients faring even more poorly using these 
cut-offs. A high SPT value of ≥11 mm and 
ImmunoCAP Ara h 2 of ≥8 kU/L carried 
the best predictive value for peanut allergy. 
These findings suggest that 95% PPVs may 
have to be tailored to our local population 
as well as to the ethnicity of the patients, and 
larger studies in unselected population are 
needed in order to do this.
The 5 patients with severe peanut allergy 
tended to be sensitised to multiple storage 
proteins (Ara h 1, 2 or 3) and had higher 
median values for specific IgE to whole 
peanut and Ara h 2, but not for SPT size.
The use of ISAC technology offers a 
wider sensitisation profile for each patient 
and enhances diagnosis of cross-reactivity. 
ISAC and ImmunoCAP technologies have 
in the past shown high concordance in the 
measurement of IgE to peanut aller gens. [18] 
Our results show that the ISAC test has lower 
sensitivity, higher specificity and generally 
lower values than the ImmunoCAP test, 
and missed 12.5% cases of peanut allergy. 
We therefore suggest that ISAC and 
ImmunoCAP tests are not equivalent or 
interchangeable.
Conclusion
Peanut allergy may be increasing in SA 
children. However, asymptomatic sensi-
tisation is also common and we need tools to 
help differentiate true allergy from possible 
asymptomatic sensitisation. Widely used 
95% PPVs for peanut allergy performed 
suboptimally in this study population of 
children with AD, particularly in Xhosa 
patients, and will need revision. A high 
SPT to peanut of ≥11 mm is valuable in 
diagnosing peanut allergy. Ara h 2 is the 
most valuable component for differentiating 
sensitisation from allergy in both Xhosa 
and mixed-race groups, little added benefit 
is derived from measuring Ara h 1 and 3, 
and Ara h 9 is the component most often 
associated with tolerance.
Table 6. Component patterns and median values in patients with severe peanut allergy
Severe peanut 
allergy 
Peanut allergy, no 
severe reaction
Difference 
(p- value)
ISAC Ara h 2-positive, n/N (%) 5/5 (100) 15/19 (78) 0.26
ISAC Ar h 1-positive, n/N (%) 5/5 (100) 7/19 (36) 0.012*
ISAC Ara h 3-positive, n/N (%) 4/5 (100) 5/19 (26) 0.027*
ImmunoCAP Ara h 1-positive, 
n/N (%)
4/5 (80) 13/19 (68) 0.61
ImmunoCAP Ara h 2-positive, 
n/N (%)
5/5 (100) 18/19 (94) 0.6
ImmunoCAP Ara h 3-positive, 
n/N (%)
4/5 (80) 9/19 (47) 0.19
ImmunoCAP Ara h 1- and 
2-positive, n/N (%)
4/5 (80) 13/19 (68) 0.61
ImmunoCAP Ara h 1-, 2- and 
3-positive, n/N (%)
4/5 (80) 9/19 (47) 0.19
ImmunoCAP to peanut (kU/L), 
median (IQR)
88 (19 - 99) 12.1 (3.3 - 53) 0.04†
ImmunoCAP Ara h 2 (kU/L), 
median (IQR)
64.5 (41.7 - 68.8) 8.98 (1.66 - 17.1) 0.01†
ISAC Ara h 2 (ISAC units), 
median (IQR)
11.0 (7.4 - 15) 2.2 (0.6 - 5.7) 0.008†
SPT size (mm), median 12 13 0.45
IQR = interquartile range.
*Statistically significant by χ2 test.
†Statistically significantly by Mann-Whitney test.
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